That clinically low HDL was associated with TNBC provides a possibility of a therapeutic target for the BC subtype that is the most aggressive, has a poor prognosis, and by definition, cannot be targeted with pharmaceutical therapy designed for ER + cancers. This evidence concerns the gene ESR1 and breast cancer.